Oncotype DX Test for Breast Cancer
Other Gene Tests
Other genome tests show promise in helping to guide treatment for early-stage breast cancer, but more research is needed.
MammaPrint looks at 70 different genes within the cells of a breast tumor and helps predict whether cancer is likely to spread beyond the breast after treatment. This test can be used for tumors that are ER+ or ER-.
The Mammostrat test measures 5 genes to calculate a risk index score for the recurrence risk of early-stage hormone receptor-positive disease.
The Prosigna assay analyzes 58 genes and calculates the recurrence risk of distant recurrence within 10 years of diagnosis of early-stage hormone receptor-positive disease in postmenopausal women (with up to 3 positive lymph nodes) after 5 years of hormonal therapy treatment.